The proportion of patients with serum phosphorus levels within target range rose from 22% to 65% within 6 months of starting ferric citrate treatment.
Up to a 49% higher risk of death observed in patients who had a 400 ng/mL increase in serum ferritin from baseline values compared with patients who had relatively stable ferritin levels.
Japanese researchers conclude that a serum ferritin level below 90 ng/mL and TSAT of 20% or higher was optimal for achieving a hemoglobin level of 10 g/dL or higher.
Researchers used pulse wave analysis to measure subendocardial viability ratio, a measure of myocardial perfusion, and its association with hemoglobin.
As red blood cell distribution width increases, so does the risk of death from any cause.
Anemic patients were 41% and 80% more likely to have coronary artery disease and peripheral artery disease than non-anemic patients.
Intravenous iron should be strongly considered for patients treated with ESAs or hemodialysis, according to reviewers.
In type 2 diabetic male patients, a low testosterone level was found to be associated with anemia. These findings are consistent with previous reports.
Significantly more patients treated with ferric citrate increased their hemoglobin levels by 1 g/dL or more over 8 weeks.
The prevalence of low hemoglobin levels increases with declining renal function.
Ferric pyrophosphate citrate delivered via dialysate or intravenously rapidly donates iron to transferrin and is rapidly cleared from the circulation.
Company asks FDA to approve ferric citrate for iron deficiency anemia in patients with non-dialysis dependent chronic kidney disease.
Decreased use of erythropoiesis-stimulating agents and an uptick in peritoneal dialysis use are among the trends.
Older men on TRT versus placebo for 1 year had improved hemoglobin levels and volumetric bone mineral density and estimated bone strength.
CKD patients with larger erythrocyte volumes had more than triple the risk of dying from cardiovascular causes, researchers reported.
Investigators observed no difference in hemoglobin level between transplant recipients and non-transplant CKD patients starting hemodialysis.
New and established peritoneal dialysis patients both showed this trend.
In a study 52.1% of patients receiving ferric citrate attained a 1.0 g/dL or greater increase in hemoglobin compared with just 19.1% receiving placebo.
New study finds no difference in all-cause and cause-specific mortality between iron sucrose and sodium ferric gluconate complex.
Use of ESAs declined while use of blood transfusions increased between 2008 and 2012.
The surface chemistry of the polymer reacts to the pH level of blood as it travels through the body.
The condition is present in more than half of Medicare patients with stage 3-5 chronic kidney disease.
US patients receive higher intravenous iron and ESA doses during the first year of hemodialysis compared with those in Europe.
Low vitamin D status was associated with a 2-fold higher risk for anemia.
Results were homogeneous, with differences in absolute mortality consistently less than 1% among the most extreme exposure categories.
Pending future research, patients should avoid taking more than 120 mg per day.
SHPT patients who received 6 months of cinacalcet treatment had a 10% increase in the odds of reaching target hemoglobin levels.
Study finds no increased risk of major adverse cardiovascular events and death.
Factors including low preoperative mean arterial BP tied to increases in eGFR, kidney injury.
Management strategy also is associated with reduced mortality risk, but not achievement of hemoglobin targets.
Renal and Urology News Articles
- For Treating Uremic Pruritus, Evidence is Strongest for Gabapentin
- IgG-Degrading Enzyme Desensitizes, Permits HLA-Incompatible Transplant
- Evaluating Practice Options in the Shifting Health Care Landscape
- Melanoma Risk Higher in Kidney Transplant Recipients
- Not All High-Risk Prostate Cancers Are the Same
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)